Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Novartis considers selling its $5B+ ophthalmology and respiratory units — report
As Novartis has been focusing its core pipeline, and spinning off its generics arm Sandoz, the company may be looking to sell even more. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
